Hikal Ltd

Hikal Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Hikal Ltd

₹ 184 4.45%
12 Jun - close price
hikal.com BSE: 524735 NSE: HIKAL
About

Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune.[1]

Key Points

Business Segments
1. Pharmaceuticals [1]: Active pharmaceutical ingredients (APIs), intermediates and advanced intermediates.
2. CDMO: ** Company has a pipeline of 13-14 products in various development stages, with 2 expected to be launched by FY26. The company focuses on NCEs and advanced intermediates, attracting growing interest from innovator companies.[2][3]
3. Crop Protection: Active ingredients, advanced intermediates, intermediates. Custom Synthesis and Contract Manufacturing of Agrochemicals, Intermediates and Specialty Chemicals. (Personal care products, Battery chemicals, and home care)
4. Research & Technology: Process development, new product development, contract and custom development. It caters to the following Industries: Pharmaceutical (Generics & Custom Manufacturing), Biotech, Animal Healthcare, Crop Protection, Specialty Chemicals and Biocides, and Food. [4] [5]

Website BSE NSE
  • Market Cap ₹ 2,269 Cr.
  • Current Price ₹ 184
  • High / Low ₹ 382 / 146
  • Stock P/E 62.3
  • Book Value ₹ 97.2
  • Dividend Yield 0.76 %
  • ROCE 3.53 %
  • ROE 2.96 %
  • Face Value ₹ 2.00
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -0.09% over past five years.
  • Company has a low return on equity of 5.42% over last 3 years.
  • Dividend payout has been low at 7.35% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
545 388 435 448 514 407 453 448 552 380 318 494 519
457 338 377 383 420 349 378 376 429 356 311 412 414
Operating Profit 88 50 58 65 94 58 75 72 124 25 7 83 106
OPM % 16% 13% 13% 14% 18% 14% 16% 16% 22% 7% 2% 17% 20%
0 1 1 0 0 0 0 4 0 1 2 -35 -40
Interest 13 14 13 14 15 20 19 19 18 17 15 16 15
Depreciation 27 28 29 29 32 32 32 33 38 39 41 41 42
Profit before tax 49 10 17 22 47 7 25 24 68 -31 -47 -9 8
Tax % 26% 29% 26% 25% 28% 26% 26% 28% 26% -26% -26% -36% -72%
36 7 12 16 34 5 18 17 50 -23 -35 -6 15
EPS in Rs 2.93 0.56 1.01 1.31 2.74 0.42 1.47 1.40 4.08 -1.84 -2.81 -0.48 1.18
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
872 926 1,014 1,296 1,590 1,507 1,720 1,943 2,023 1,785 1,860 1,713
689 745 814 1,054 1,291 1,234 1,398 1,602 1,765 1,518 1,531 1,492
Operating Profit 182 181 200 242 298 273 323 341 258 267 328 220
OPM % 21% 20% 20% 19% 19% 18% 19% 18% 13% 15% 18% 13%
2 2 1 4 2 -12 5 5 5 2 5 -73
Interest 60 62 48 49 58 52 36 31 48 56 75 62
Depreciation 64 67 69 86 93 82 85 96 109 118 134 164
Profit before tax 60 53 83 112 149 127 206 219 105 95 124 -78
Tax % 32% 22% 15% 31% 31% 33% 36% 27% 26% 27% 27% -38%
41 41 71 77 103 84 133 161 78 70 91 -49
EPS in Rs 3.29 3.35 5.73 6.26 8.36 6.85 10.80 13.02 6.36 5.64 7.37 -3.95
Dividend Payout % 20% 20% 14% 13% 14% 18% 19% 12% 19% 21% 11% -10%
Compounded Sales Growth
10 Years: 6%
5 Years: 0%
3 Years: -5%
TTM: -8%
Compounded Profit Growth
10 Years: -1%
5 Years: -23%
3 Years: -22%
TTM: -60%
Stock Price CAGR
10 Years: 6%
5 Years: -17%
3 Years: -17%
1 Year: -51%
Return on Equity
10 Years: 10%
5 Years: 8%
3 Years: 5%
Last Year: 3%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 16 16 16 16 25 25 25 25 25 25 25 25
Reserves 517 548 589 653 732 792 909 1,043 1,109 1,163 1,238 1,174
547 505 598 635 661 646 610 675 748 818 765 684
212 206 177 237 268 306 370 470 504 482 502 483
Total Liabilities 1,293 1,276 1,379 1,542 1,686 1,768 1,913 2,213 2,385 2,487 2,529 2,365
639 623 668 634 713 735 713 879 948 1,071 1,364 1,333
CWIP 62 66 63 118 79 161 254 295 412 414 121 94
Investments 3 3 4 3 1 1 1 11 5 5 10 10
589 584 645 788 893 871 946 1,028 1,020 997 1,034 928
Total Assets 1,293 1,276 1,379 1,542 1,686 1,768 1,913 2,213 2,385 2,487 2,529 2,365

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
102 186 163 139 186 285 229 294 315 187 280 302
-43 -64 -103 -110 -125 -164 -156 -284 -292 -174 -136 -145
-69 -124 -63 -25 -55 -101 -97 -6 -8 -27 -144 -160
Net Cash Flow -10 -2 -2 4 6 20 -24 4 15 -14 0 -3
Free Cash Flow 54 127 58 33 57 127 71 21 13 -17 144 154
CFO/OP 63% 110% 92% 68% 73% 113% 85% 107% 134% 81% 94% 144%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 54 44 92 81 80 82 103 82 80 113 103 94
Inventory Days 268 229 189 158 156 147 107 121 104 134 146 172
Days Payable 117 101 93 86 68 95 92 91 103 123 133 128
Cash Conversion Cycle 205 173 188 153 168 135 118 112 81 124 116 138
Working Capital Days -13 29 43 29 45 28 39 26 39 39 37 41
ROCE % 11% 11% 12% 13% 15% 14% 16% 15% 8% 8% 10% 4%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Employees
Number

Log in to view insights

Please log in to see hidden values.

Login
Total Reactor Capacity
m3
Total Sales Volume (Active Ingredients & Intermediates)
MT
Commercialized APIs (Pharma)
Number
Commercialized Products (Crop Protection)
Number
Active Drug Master Files (DMFs)
Number
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85% 68.85%
4.57% 4.81% 6.14% 6.55% 6.66% 6.78% 6.06% 5.70% 5.35% 4.23% 2.31% 1.44%
2.78% 3.11% 3.15% 3.53% 3.17% 3.58% 3.48% 3.80% 4.03% 5.15% 7.05% 7.20%
23.79% 23.22% 21.85% 21.06% 21.32% 20.79% 21.61% 21.65% 21.76% 21.75% 21.78% 22.51%
No. of Shareholders 75,11076,12674,65771,84070,97871,91271,80168,90771,39173,40474,11774,270

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls